The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
Several published clinical trials have shown the superiority of immunotherapy in neoadjuvant setting. Here we conducted this real world study to see whether neoadjuvant immunotherapy would bring MPR and survival benefits in NSCLC, for example, single agent immunotherapy or immunotherapy combination with chemotherapy. Furthermore biomarker analysis would be also performed to achieve personalized neoadjuvant immunotherapy.
• Written informed consent provided
• Males or females aged ≥18 years
• Able to comply with the required protocol and follow-up procedures、
• Pathologically diagnosed of potentially resectable non-small cell lung cancer with stage II-IIIA (TNM 8th edition)
• Measurable disease must be characterized according to RECIST 1.1 criteria
• ECOG performance status 0-1
• Regardless of PD-L1 expression
• EGFR mutation (-) and ALK translocation (-)
• Pulmonary function could be well tolerated by lobectomy or pneumonectomy